{
  "id": 3446495,
  "title": "Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch",
  "url": "https://urgent.news/2026/08/26/hanmi-pharm-in-spotlight-as-koreas-1st-obesity-drug-nears-launch-3446495",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T06:42:03.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times-koreatimes",
    "url": "https://www.koreatimes.co.kr/business/companies/20260826/hanmi-pharm-in-spotlight-as-koreas-1st-obesity-drug-nears-launch"
  },
  "original_language": "en",
  "account": null,
  "summary": "Hanmi Pharmaceutical is gaining attention as it prepares to launch Korea’s first glucagon-like peptide-1 (GLP-1)-based obesity drug, Eppe, while also signing a licensing deal worth up to $2.3 billion for a separate obesity drug candidate. Analysts at domestic brokerages have raised their price target on Hanmi Pharm, citing the company’s potential in obesity drugs.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Korea Times",
        "title": "Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch",
        "url": "https://urgent.news/2026/08/26/hanmi-pharm-in-spotlight-as-koreas-1st-obesity-drug-nears-launch",
        "published": "2026-08-26T06:37:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}